Российские пациенты начали получать новый радиофармпрепарат для борьбы с раком на основе актиния-225
Шесть человек, проходящих лечение в Федеральном научно-клиническом центре медицинской радиологии и онкологии в Димитровграде, стали первыми пользователями радиофармпрепарата актиния-225-ПСМА местного производства. Этот препарат предназначен для терапии неоперабельных метастатических форм рака и был разработан при сотрудничестве с Научно-исследовательским институтом атомных реакторов, который входит в состав госкорпорации «Росатом».
Актиний-225, производимый в ГНЦ НИИАР, представляет собой альфа-эмиттер, который высокоэффективен в адресной терапии онкологических заболеваний.
Ученые отмечают, что терапия актинием-225 особенно эффективна для лечения кастрационно-резистентного рака предстательной железы, который трудно поддается традиционным методам.
Новый радиофармпрепарат способствует обеспечению доступности жизненно важного лечения для российских больниц и уменьшает зависимость от зарубежных поставок.
В избранное
Чтобы оставлять комментарии, нужно войти или зарегистрироваться.
Комментарии (39)
I don’t think the title of your article matches the content lol. Just kidding, mainly because I had some doubts after reading the article.
Your article helped me a lot, is there any more related content? Thanks!
Your point of view caught my eye and was very interesting. Thanks. I have a question for you.
Your point of view caught my eye and was very interesting. Thanks. I have a question for you.
Thanks for sharing. I read many of your blog posts, cool, your blog is very good.
I don’t think the title of your article matches the content lol. Just kidding, mainly because I had some doubts after reading the article.
Can you be more specific about the content of your article? After reading it, I still have some doubts. Hope you can help me.
Can you be more specific about the content of your article? After reading it, I still have some doubts. Hope you can help me.
Can you be more specific about the content of your article? After reading it, I still have some doubts. Hope you can help me.
Thanks for sharing. I read many of your blog posts, cool, your blog is very good. https://www.binance.com/register?ref=P9L9FQKY
Your article helped me a lot, is there any more related content? Thanks!
Your point of view caught my eye and was very interesting. Thanks. I have a question for you.
I don’t think the title of your article matches the content lol. Just kidding, mainly because I had some doubts after reading the article.
I don’t think the title of your article matches the content lol. Just kidding, mainly because I had some doubts after reading the article.
Thank you for your sharing. I am worried that I lack creative ideas. It is your article that makes me full of hope. Thank you. But, I have a question, can you help me?
Can you be more specific about the content of your article? After reading it, I still have some doubts. Hope you can help me.
I don’t think the title of your article matches the content lol. Just kidding, mainly because I had some doubts after reading the article.
Your article helped me a lot, is there any more related content? Thanks!
BjP8azmJkiU
Xy6DUOc9ZEX
tzqgfWgmLAo
wl2fr1IyADc
j9ykxWvEimZ
SsrW4lo9eYI
zxuA4mGd9Mg
mLXMmqxkDSu
tGReL1IO1s7
3Suv9byA2FY
VRDGAQFuGHZ
wpnRgrmMY8i
ZWcZK8yoQU8
AqEUQQuXdWv
k8E1uD2y0M9
roPgvCk2Aij
gwwJze7Ei1F
vADqBEfIP3d
I don’t think the title of your article matches the content lol. Just kidding, mainly because I had some doubts after reading the article.
Thanks for sharing. I read many of your blog posts, cool, your blog is very good.
Thank you for your sharing. I am worried that I lack creative ideas. It is your article that makes me full of hope. Thank you. But, I have a question, can you help me?